News
- 2025.08.04
- 半期報告書－第21期(2025/01/01－2025/12/31) (Japanese only)
- 2025.08.04
- Notice Regarding Publication of a Review Article on Evaluation of Brincidofovir as Potential Treatment for Mpox by Licensor Emergent BioSolutions
- 2025.08.01
- Notice of Appointment of Corporate Officer
- 2025.07.31
- Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2025 [Japanese GAAP]
- 2025.07.28
- SymBio to Present Preclinical Data on Brincidofovir in Head and Neck Cancer at ESMO 2025 Congress
Selection News
- 2025.08.05
- 中間決算説明会資料（2025年12月期）(Japanese only)
- 2025.06.30
- 「ブリンシドフォビル開発最前線」を追加しました。
- 2025.06.03
- Key person interview: Updated the Page
- 2025.05.16
- 株主通信「SymBio VISION vol.27」(Japanese only)
- 2025.03.28
- 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
- 2025.03.28
- 第20期定時株主総会の動画を掲載しました。(Japanese only)
- 2025.02.26
- 2024年12月期決算説明会の動画を掲載しました。(Japanese only)
- 2025.02.13
- 決算説明会資料（2024年12月期）(Japanese only)
- 2024.08.13
- Article on 2024 1H Earnings Call Featured in Nikkei Biotech Online (Japanese only)
Source: Nikkei Biotech ONLINE, 2024.08.07
Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.
- 2023.11.17
- Notice of Relocation of Head Office